Drug Trial Radar · NCT05915442
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
23
Planned (sponsor's estimate)
Start
Jul 1, 2023
Primary completion
Dec 1, 2026
Study completion Dec 2028
Sponsor
- Lead sponsor
- Catherine SpinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arcus Biosciences, Inc.
- First posted
- Jun 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men with hormone sensitive oligometastatic prostate cancer. The study aims to test the hypothesis that targeted inhibition of the adenosine signaling axis (quemliclustat (CD73 antagonist) + etrumadenant (A2AR/A2BR antagonist)) and immune checkpoint inhibition (zimberelimab, α-PD-1) in combination with metastasis-directed stereotactic body radiation therapy (SBRT) will improve local control, progression-free survival (PFS), and hormone therapy-free survival and mitigate immunosuppressive changes to the tumor microenvironment (TME), compared to SBRT alone.
Conditions
- Oligometastatic Prostate Cancer
Interventions
QuemliclustatDrug
100mg IV once every two weeks
EtrumadenantDrug
150 mg orally (PO) once a day (QD)
ZimberelimabDrug
240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT
Stereotactic Body Radiation TherapyRadiation
Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biochemical recurrence-free survival at 12-monthsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.